News|Videos|April 25, 2025

Drug Digest: Keeping Pace with Progressive Technologies in Biopharma Development

This episode of Drug Digest will discuss where the significant bottlenecks are in the development and manufacturing of new molecules resulting from progressive technologies, such as AI and ML, and how best to approach these challenges.

The biopharma industry is at a time where progressive technologies such as artificial intelligence, machine learning, and digitalization technologies are making a significant impact on how drug discovery, development, and manufacturing are being driven. Yet the question remains as to how the industry itself is keeping up with the fast-paced innovation churning out from these advanced technologies. This episode of Drug Digest will examine where the significant bottlenecks are in the development and manufacturing of new molecules resulting from these progressive technologies, and how best to approach these challenges.

Interview featuring

  • Kevin Dondarski, Principal, Life Sciences R&D, Deloitte Consulting
  • Maryland Franklin, PhD, Vice-President and Enterprise Head, Cell and Gene Therapy, Labcorp
  • Lidia Serina, PhD, head of Development Services at Simtra BioPharma Solutions
  • Sean Tucker, PhD, Founder and Chief Scientific Officer, Vaxart

Sponsors

This episode of Drug Digest is sponsored by:

  • Biovectra
  • Eppendorf
  • Kindeva
  • Veltek

About Drug Digest

Drug Digest is a tech talk video series with the Pharmaceutical Technology® editors, who interview industry experts to discuss the emerging opportunities, obstacles, and advances in the pharmaceutical and biopharmaceutical industry for the research, development, formulation, analysis, upstream and downstream processing, manufacturing, supply chain, and packaging of drug products.

Upcoming episodes

  • May/June 2025: Solid Dosage Formulation Trends
  • July/August 2025: Large-Molecule Manufacturing Trends
  • September 2025: Developments in Small-Molecule APIs, Excipients, and Ingredients

Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.